Advanced search
Publication Cover
Emerging Microbes & Infections Volume 11, 2022 - Issue 1
Submit an article Journal homepage
5,366
Views
24
CrossRef citations to date
0
Altmetric
Coronaviruses

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants

Zhuxiang Zhaoa Department of Infectious Disease, Respiratory and Critical Care Medicine, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, People’s Republic of China
,
Tingting Cuib State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China;c Guangzhou Laboratory, Bioland, Guangzhou, People’s Republic of China
,
Mingzhu Huangb State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China;c Guangzhou Laboratory, Bioland, Guangzhou, People’s Republic of China
,
Shuo Liud National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products & NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing, People’s Republic of China
,
Xiaoling Sub State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China;c Guangzhou Laboratory, Bioland, Guangzhou, People’s Republic of China
,
Guichang Lib State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China;c Guangzhou Laboratory, Bioland, Guangzhou, People’s Republic of China
,
Tao Songb State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China;c Guangzhou Laboratory, Bioland, Guangzhou, People’s Republic of China
,
Weidong Lib State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China;c Guangzhou Laboratory, Bioland, Guangzhou, People’s Republic of China
,
Nanshan Zhongb State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China;c Guangzhou Laboratory, Bioland, Guangzhou, People’s Republic of China
,
Miao Xud National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products & NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing, People’s Republic of ChinaCorrespondence[email protected]
,
Xiaoyun Yangb State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China;c Guangzhou Laboratory, Bioland, Guangzhou, People’s Republic of ChinaCorrespondence[email protected]
,
WeiJin Huangd National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products & NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing, People’s Republic of ChinaCorrespondence[email protected]
&
Zhongfang Wangb State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China;c Guangzhou Laboratory, Bioland, Guangzhou, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 829-840 | Received 12 Jan 2022, Accepted 25 Feb 2022, Published online: 15 Mar 2022

Figures & data

Figure 1. Antibody response after two-dose of inactivated vaccination and booster vaccination with RBD subunit or inactivated vaccination. (a) Total anti-S + N antibody titre of two doses of inactivated vaccines, n = 33 at D7, D14, 1, 3 M, n = 21 at 6 M. (b) Total anti-RBD antibody titre of two doses of inactivated vaccines, n = 33 at D7, D14, 1M, 3M, n = 21 at 6M. (c) Neutralizing antibody titre based on ACE2 competition assay of two doses of inactivated vaccines, n = 33 at D7, D14, 1M, 3M, n = 21 at 6M. (d) Neutralizing antibody titres against Wuhan-1 and Omicron strains for two doses of inactivated vaccines, n = 20 for Wuhan-1 and Omicron at 1M, n = 14 for Wuhan-1 and Omicron at 3M. (e) Comparison of total anti-S + N antibody titer between I-I-I and I-I-S, n = 28 in I-I-I, n = 27 in I-I-S. (f) Antibody response in booster groups evaluated by anti-RBD IgG, n = 28 in I-I-I, n = 27 in I-I-S. (g) Antibody response in booster groups evaluated by Neutralizing antibody titre based on ACE2 competition assay, n = 28 in I-I-I, n = 27 in I-I-S. ns, not significant; *P < 0.05, **P < 0.01, ****P < 0.0001.

Figure 1. Antibody response after two-dose of inactivated vaccination and booster vaccination with RBD subunit or inactivated vaccination. (a) Total anti-S + N antibody titre of two doses of inactivated vaccines, n = 33 at D7, D14, 1, 3 M, n = 21 at 6 M. (b) Total anti-RBD antibody titre of two doses of inactivated vaccines, n = 33 at D7, D14, 1M, 3M, n = 21 at 6M. (c) Neutralizing antibody titre based on ACE2 competition assay of two doses of inactivated vaccines, n = 33 at D7, D14, 1M, 3M, n = 21 at 6M. (d) Neutralizing antibody titres against Wuhan-1 and Omicron strains for two doses of inactivated vaccines, n = 20 for Wuhan-1 and Omicron at 1M, n = 14 for Wuhan-1 and Omicron at 3M. (e) Comparison of total anti-S + N antibody titer between I-I-I and I-I-S, n = 28 in I-I-I, n = 27 in I-I-S. (f) Antibody response in booster groups evaluated by anti-RBD IgG, n = 28 in I-I-I, n = 27 in I-I-S. (g) Antibody response in booster groups evaluated by Neutralizing antibody titre based on ACE2 competition assay, n = 28 in I-I-I, n = 27 in I-I-S. ns, not significant; *P < 0.05, **P < 0.01, ****P < 0.0001.

Figure 2. Neutralizing activity comparison between I-I-I and I-I-S. (a) Pseudovirus-based neutralizing response after two strategies of booster vaccinations against Wuhan-1 and VOCs, including, B.1.1.7 (Alpha Variant), B.1.351 (Beta Variant), P.1 (Gamma Variant), B.1.617.2 (Delta Variant) and C37 (Lambda Variant) strains. (b) EC50 titer after third shot of inactivated vaccine against Wuhan-1 stain (n = 20). (c) EC50 titer after third shot of RBD recombinant subunit vaccine against Wuhan-1 stain (n = 25). (d) Comparison of the neutralizing titer based on pVNT against Omicron strain between I-I-S (n = 25) and I-I-I (n = 20). (e) Neutralizing antibody titres against Wuhan-1 strain and Omicron strain for I-I-S (n = 25) and I-I-I (n = 20) evaluated by conventional virus neutralization test. **P < 0.01, ***P < 0.001, ****P < 0.0001.

Figure 2. Neutralizing activity comparison between I-I-I and I-I-S. (a) Pseudovirus-based neutralizing response after two strategies of booster vaccinations against Wuhan-1 and VOCs, including, B.1.1.7 (Alpha Variant), B.1.351 (Beta Variant), P.1 (Gamma Variant), B.1.617.2 (Delta Variant) and C37 (Lambda Variant) strains. (b) EC50 titer after third shot of inactivated vaccine against Wuhan-1 stain (n = 20). (c) EC50 titer after third shot of RBD recombinant subunit vaccine against Wuhan-1 stain (n = 25). (d) Comparison of the neutralizing titer based on pVNT against Omicron strain between I-I-S (n = 25) and I-I-I (n = 20). (e) Neutralizing antibody titres against Wuhan-1 strain and Omicron strain for I-I-S (n = 25) and I-I-I (n = 20) evaluated by conventional virus neutralization test. **P < 0.01, ***P < 0.001, ****P < 0.0001.

Table 1. Neutralizing antibody titre against Wuhan-1 strain and different variants of concern.

Figure 3. Duration of neutralizing antibody titres after booster vaccinations. (a, b) Long-term profile of EC50 titers based on pVNT against Wuhan-1 strain and Omicron strain for I-I-I group (n = 20 at D0 and D14, n = 13 at 1M). (c, d) Long-term profile of EC50 titres based on pVNT against Wuhan-1 strain and Omicron strain for I-I-S group (n = 25 at D0 and D14, n = 23 at 1M, n = 10 at 3M). (e, f) NT50 titres against Wuhan-1 strain and Omicron strain at D0, D14 and 1M post inactivated booster vaccination (n = 20 at D0 and D14, n = 13 at 1M). (g, h) NT50 titres against Wuhan-1 strain and Omicron strain at D0, D14, 1M and 3M post RBD subunit booster vaccination (n = 25 at D0 and D14, n = 23 at 1M, n = 10 at 3M). ns, not significant; *P < 0.05, ***P < 0.001, ****P < 0.0001.

Figure 3. Duration of neutralizing antibody titres after booster vaccinations. (a, b) Long-term profile of EC50 titers based on pVNT against Wuhan-1 strain and Omicron strain for I-I-I group (n = 20 at D0 and D14, n = 13 at 1M). (c, d) Long-term profile of EC50 titres based on pVNT against Wuhan-1 strain and Omicron strain for I-I-S group (n = 25 at D0 and D14, n = 23 at 1M, n = 10 at 3M). (e, f) NT50 titres against Wuhan-1 strain and Omicron strain at D0, D14 and 1M post inactivated booster vaccination (n = 20 at D0 and D14, n = 13 at 1M). (g, h) NT50 titres against Wuhan-1 strain and Omicron strain at D0, D14, 1M and 3M post RBD subunit booster vaccination (n = 25 at D0 and D14, n = 23 at 1M, n = 10 at 3M). ns, not significant; *P < 0.05, ***P < 0.001, ****P < 0.0001.

Figure 4. Neutralizing antibody titres against monoclonal antibodies 13G2 and 08B3 after booster vaccinations. (a) Comparison of neutralizing antibody titers based on monoclonal antibody 13G2 between I-I-I and I-I-S. n = 25 in I-I-I, n = 27 in I-I-S. (b) Neutralizing antibody titres against monoclonal antibody 08B3 for I-I-I and I-I-S group samples. n = 25 in I-I-I, n = 27 in I-I-S. ns, not significant; *P < 0.05, **P < 0.01, ****P < 0.0001.

Figure 4. Neutralizing antibody titres against monoclonal antibodies 13G2 and 08B3 after booster vaccinations. (a) Comparison of neutralizing antibody titers based on monoclonal antibody 13G2 between I-I-I and I-I-S. n = 25 in I-I-I, n = 27 in I-I-S. (b) Neutralizing antibody titres against monoclonal antibody 08B3 for I-I-I and I-I-S group samples. n = 25 in I-I-I, n = 27 in I-I-S. ns, not significant; *P < 0.05, **P < 0.01, ****P < 0.0001.

Figure 5. The portion of neutralizing epitopes targeted by booster vaccinations. (a) The portion of neutralizing antibody titre compared to total anti-S + N antibody for I-I-I and I-I-S groups. (b) The portion of neutralizing antibody titre compared to total anti-RBD antibody for I-I-I and I-I-S groups. The portion of neutralizing antibodies represented by monoclonal antibodies 13G2 (c) and 08B3 (d) compared to neutralizing antibody for I-I-I and I-I-S groups at D14 post booster vaccination. n = 20 in I-I-I, n = 25 in I-I-S. ns, not significant; *P < 0.05, ***P < 0.001, ****P < 0.0001.

Figure 5. The portion of neutralizing epitopes targeted by booster vaccinations. (a) The portion of neutralizing antibody titre compared to total anti-S + N antibody for I-I-I and I-I-S groups. (b) The portion of neutralizing antibody titre compared to total anti-RBD antibody for I-I-I and I-I-S groups. The portion of neutralizing antibodies represented by monoclonal antibodies 13G2 (c) and 08B3 (d) compared to neutralizing antibody for I-I-I and I-I-S groups at D14 post booster vaccination. n = 20 in I-I-I, n = 25 in I-I-S. ns, not significant; *P < 0.05, ***P < 0.001, ****P < 0.0001.

Figure 6. Different composite pattern between booster vaccination and breakthrough infection. (a) Neutralizing antibody titre against Wuhan-1 stain for samples collected at D14 post booster vaccinations and D14 post breakthrough infection. n = 20 in I-I-I, n = 10 in I-I-S, n = 16 in recovered Delta breakthrough patients. (b, c) The portion of neutralizing antibody titre compared to total anti-S + N and anti-RBD antibody at 1M post two-dose vaccination, post booster vaccinations and post breakthrough infection. n = 20 in I-I, n = 13 in I-I-I, n = 23 in I-I-S, n = 11 in Delta-Recovery. (d, e) The portion of neutralizing antibodies represented by monoclonal antibody 13G2 or 08B3 compared to total neutralizing antibody for vaccination samples and breakthrough infection samples. n = 13 in I-I-I, n = 23 in I-I-S, n = 11 in Delta-Recovery. ns, not significant; *P < 0.05, ***P < 0.001, ****P < 0.0001.

Figure 6. Different composite pattern between booster vaccination and breakthrough infection. (a) Neutralizing antibody titre against Wuhan-1 stain for samples collected at D14 post booster vaccinations and D14 post breakthrough infection. n = 20 in I-I-I, n = 10 in I-I-S, n = 16 in recovered Delta breakthrough patients. (b, c) The portion of neutralizing antibody titre compared to total anti-S + N and anti-RBD antibody at 1M post two-dose vaccination, post booster vaccinations and post breakthrough infection. n = 20 in I-I, n = 13 in I-I-I, n = 23 in I-I-S, n = 11 in Delta-Recovery. (d, e) The portion of neutralizing antibodies represented by monoclonal antibody 13G2 or 08B3 compared to total neutralizing antibody for vaccination samples and breakthrough infection samples. n = 13 in I-I-I, n = 23 in I-I-S, n = 11 in Delta-Recovery. ns, not significant; *P < 0.05, ***P < 0.001, ****P < 0.0001.

Figure 7. Cell responses after booster vaccinations. (a) Representative dot plots showing IFN-γ and TFN-α expression in CD4 + and CD8+ T cells after peptides stimulation at D14 post booster vaccination. (b) The percentages (left panel) and number/million PBMC (right panel) of IFN-γ+TFN-α+ CD4+ T cells after booster vaccination. (c) The percentages (left panel) and number/million PBMC (right panel) of IFN-γ+TFN-α+ CD8+ T cells after booster vaccination. n = 24 in I-I-I, n = 27 in I-I-S. IFN-γ+TFN-α+ CD4+ T cell response (d) and IFN-γ+TFN-α+ CD8+ T cell response at different time points post RBD recombinant subunit booster vaccination (e). n = 27 at D0 and D14, n = 23 at 1M, n = 10 at 3M. ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Figure 7. Cell responses after booster vaccinations. (a) Representative dot plots showing IFN-γ and TFN-α expression in CD4 + and CD8+ T cells after peptides stimulation at D14 post booster vaccination. (b) The percentages (left panel) and number/million PBMC (right panel) of IFN-γ+TFN-α+ CD4+ T cells after booster vaccination. (c) The percentages (left panel) and number/million PBMC (right panel) of IFN-γ+TFN-α+ CD8+ T cells after booster vaccination. n = 24 in I-I-I, n = 27 in I-I-S. IFN-γ+TFN-α+ CD4+ T cell response (d) and IFN-γ+TFN-α+ CD8+ T cell response at different time points post RBD recombinant subunit booster vaccination (e). n = 27 at D0 and D14, n = 23 at 1M, n = 10 at 3M. ns, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Supplemental material

Supplemental Material

Download MS Word (71.6 KB)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.